Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?

Guntram Schernthaner, R. J. Chilton

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Meta-analyses of clinical trials suggest that the use of the thiazolidinedione (TZD), rosiglitazone, in patients with type 2 diabetes mellitus may increase the risk of myocardial ischaemic events by 30-40%. Although these controversial data must be interpreted with caution, in the absence of definitive prospective cardiovascular (CV) outcomes data, they represent a prominent source of evidence concerning the CV safety of rosiglitazone. The results of meta-analyses and a large randomized-controlled CV outcomes trial provide strong evidence that pioglitazone does not increase the risk of coronary events. This article clarifies the clinical significance of these meta-analytical findings alongside other sources of evidence and assesses their impact on evolving treatment guidelines and recommendations for the use of TZDs in patients with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)1023-1035
Number of pages13
JournalDiabetes, Obesity and Metabolism
Issue number12
StatePublished - Dec 2010


  • Cardiovascular disease
  • Myocardial infarction
  • Pioglitazone
  • Rosiglitazone
  • Thiazolidinediones

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?'. Together they form a unique fingerprint.

Cite this